Abstracts tagged "Systemic sclerosis"

Abstract Number: L09 • ACR Convergence 2020
A Phase 2a Randomized, Double-blind, Placebo-controlled Study of Ziritaxestat in Early Diffuse Cutaneous Systemic Sclerosis (NOVESA)
Dinesh Khanna¹, Christopher Denton², Daniel Furst³, Maureen Mayes⁴, Marco Matucci-Cerinic⁵, Vanessa Smith⁶, Dick de Vries⁷, Liesbeth Deberdt⁸, Pieter‑Jan Stiers⁸, Niyati Prasad⁸ and Sohail Ahmed⁹, ¹University of Michigan, Ann Arbor, MI, ²Royal Free Hospital, University College London, London, United Kingdom, ³David Geffen School of Medicine at UCLA, Los Angeles, CA, ⁴University of Texas Health Science Center at Houston, Houston, TX, ⁵Università degli Studi di Firenze, Firenze, Italy, ⁶Ghent University Hospital, Ghent, Belgium, ⁷Galapagos BV, Leiden, Netherlands, ⁸Galapagos NV, Mechelen, Belgium, ⁹Ahmed Science Medicine, Basel, Switzerland
Background/Purpose: There is a high unmet need for systemic sclerosis (SSc) treatments. Ziritaxestat (ziri; GLPG1690) is an autotaxin inhibitor with a novel mechanism of action.…
Abstract Number: 0396 • ACR Convergence 2020
Safety and Efficacy of Subcutaneous Tocilizumab in Systemic Sclerosis: Results from the Open-Label Period of a Phase 3 Trial
Dinesh Khanna¹, Celia J. F. Lin², Helen Spotswood³, Jeffrey Siegel², Daniel Furst*⁴ and Christopher Denton⁵, ¹University of Michigan, Ann Arbor, MI, ²Genentech, South San Francisco, CA, ³Roche Products Ltd, Welwyn Garden City, United Kingdom, ⁴Department of Medicine, Division of Rheumatology, University of California at Los Angeles, Los Angeles, California, USA, Los Angeles, CA, ⁵University College London, London, United Kingdom
Background/Purpose: The anti–interleukin-6 (IL-6) receptor-α antibody tocilizumab (TCZ) demonstrated skin score improvement and forced vital capacity (FVC) preservation in patients with systemic sclerosis (SSc) in…
Abstract Number: 1070 • ACR Convergence 2020
Scleromyositis Is Associated with Distinct Muscle Vasculopathic Features
Océane Landon-Cardinal¹, Valérie Leclair², Yves Troyanov³, Alain Meyer⁴, Sabrina Hoa¹, Josiane Bourré-Tessier¹, Valérie Nadon⁵, Julie Drouin⁶, Jason Karamchandani⁷, Erin O'Ferrall⁸, Minoru Satoh⁹, Marvin Fritzler¹⁰, Jean-Luc Senécal¹, Marie Hudson² and Benjamin Ellezam¹¹, ¹Division of Rheumatology, Centre hospitalier de l'Université de Montréal, Montréal, QC, Canada, ²Division of Rheumatology, Jewish General Hospital, Montréal, QC, Canada, ³Division of Rheumatology, Hôpital du Sacré-Coeur, Montréal, QC, Canada, ⁴Service de rhumatologie et Centre de références des maladies autoimmunes rares, Hôpitaux universitaires de Strasbourg, Strasbourg, Alsace, France, ⁵Division of Rheumatology, Hôpital Notre-Dame, Montreal, Québec, Canada, Montréal, QC, Canada, ⁶Division of Rheumatology, Centre hospitalier régional de Trois-Rivières, Trois-Rivières, QC, Canada, ⁷Department of Pathology, Montreal Neurological Institute and Hospital, Montreal, QC, Canada, ⁸Department of Neurology and Neurosurgery, Montreal Neurological Institute and Hospital, Montreal, QC, Canada, ⁹Department of Clinical Nursing, University of Occupational and Environmental Health, Kitakyushu, Japan, ¹⁰Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ¹¹Division of Pathology, Centre hospitalier universitaire Sainte-Justine, Montréal, QC, Canada
Background/Purpose: Scleromyositis (SM) is an emerging subgroup of autoimmune myositis (AIM) associated with features of systemic sclerosis (SSc). Muscle biopsy studies are sparse and have…
Abstract Number: 1526 • ACR Convergence 2020
Single Cell Analysis of Skin and Blood of Scleroderma Patients Towards Identification of New Disease Mechanisms, Prognostic Biomarkers and Potential Therapeutic Targets
Chamutal Gur¹, Postil 158626², Hagit Peleg³, Suhail Aamar³, Fadi Kharouf³, Anat Elazary³, Yolanda Braun-Moscovici Braun-Moscovici⁴, Shuang-Yin Wang⁵ and Ido Amit⁵, ¹Hadassah Medical Center, Hebrew University, Laboratory for Immuno-Genomics, Weizmann Institute of Science, Jerusalem, Israel, ²Rambam Health Care Campus, Technion-Israeli Institute of Technology, Kiriat Mozkin, HaZafon, Israel, ³Hadassah Medical Center, Jerusalem, Israel, ⁴Rambam Health Care Campus, Technion-Israeli Institute of Technology, Haifa, Israel, ⁵Laboratory for Immuno-Genomics, Weizmann Institute of Science, Rehovot, Israel
Background/Purpose: Systemic sclerosis (SSc) is characterized by fibrosis, microangiopathy and immune dysregulation. Despite many years of research, the pathogenesis of SSc is poorly understood; there…
Abstract Number: 0397 • ACR Convergence 2020
Assessing Adherence to Screening of Systemic Sclerosis-Related Lung Disease
Matthew Herrmann¹ and Zineb Aouhab¹, ¹Loyola University Medical Center, Maywood, IL
Background/Purpose: Feared complications of systemic sclerosis (SSc) affect the pulmonary system, with pulmonary hypertension and interstitial lung disease being common causes of mortality. Baseline and…
Abstract Number: 1128 • ACR Convergence 2020
The Diagnosis of Systemic Sclerosis as a Traumatic Experience: Patients’ Reactions to the Diagnostic Process
Fennell Patricia¹, Lee Shapiro², Nancy Dorr³, Roberta Lukasiewicz⁴, Frank Houser⁵ and Madison Taylor⁶, ¹Albany Health Management Associates, Steffens Scleroderma Foundation, Albany, NY, ²Albany Medical College, Stillwater, NY, ³The College of Saint Rose, Albany, NY, ⁴Steffens Scleroderma Foundation, Albany, NY, ⁵The College of Saint Rose, Nassau, NY, ⁶The College of Saint Rose, Mississauga, ON, Canada
Background/Purpose: Both the process of being diagnosed with a chronic illness and the illness itself can be a traumatizing experience (1). The current study examined…
Abstract Number: 1905 • ACR Convergence 2020
Soluble Guanylate Cyclase Reduced the Gastrointestinal Fibrosis in Bleomycin-induced Mouse Model of Systemic Sclerosis
Yuzuru Yamamoto¹, Takaichi Okano², Takumi Nagamoto², Yoshikazu Fujikawa³, Yoshihide Ichise², Hirotaka Yamada², Ikuko Naka², Yo Ueda⁴, Kengo Akashi⁵, Sho Sendo⁶, Akira Onishi⁵, Jun Saegusa⁷ and Akio Morinobu⁵, ¹Kobe University, Kobe-city, Japan, ²Kobe University, Kobe, Japan, ³Kobe University, Kobe city, Japan, ⁴Kobe UniversityRheumatology and Clinical Immunology, Kobe University Hospital, Kobe, Japan, ⁵Rheumatology and Clinical Immunology, Kobe University Hospital, Kobe, Japan, ⁶Kobe University, Kobe, ⁷Department of Clinical Laboratory, Kobe University Hospital, Kobe, Japan
Background/Purpose: Systemic sclerosis (SSc) is a chronic autoimmune-mediated connective tissue disorder. Although the etiology of the disease remains undermined, SSc is characterized by fibrosis and…
Abstract Number: 0398 • ACR Convergence 2020
Chest CT Ordering Practices at Expert Scleroderma Centers in the United States
Elana Bernstein¹, John VanBuren², Shervin Assassi³, Flavia Castelino⁴, Lorinda Chung⁵, Chase Correia⁶, Luke Evnin⁷, Tracy Frech⁸, Emily Startup², Jessica Gordon⁹, Faye Hant¹⁰, Laura Hummers¹¹, Nora Sandorfi¹², Ami Shah¹³, Victoria Shanmugam¹⁴, Virginia Steen¹⁵ and Dinesh Khanna¹⁶, ¹Columbia University, New York, NY, ²University of Utah, Salt Lake City, UT, ³University of Texas Houston McGovern Medical School, Division of Rheumatology and Clinical Immunogenetics, Houston, TX, ⁴Massachusetts General Hospital/Harvard Medical School, Boston, MA, ⁵Stanford University School of Medicine and Palo Alto VA Health Care System, Palo Alto, CA, ⁶Northwestern University, Chicago, IL, ⁷Scleroderma Research Foundation, Brisbane, CA, ⁸University of Utah and Salt Lake Veterans Affair Medical Center, Salt Lake City, UT, ⁹Hospital for Special Surgery, New York, NY, ¹⁰Medical University of South Carolina, Charleston, SC, ¹¹Johns Hopkins Univerisity, Ellicott City, MD, ¹²University of Pennsylvania, Philadelphia, PA, ¹³Johns Hopkins University School of Medicine, Ellicott City, MD, ¹⁴The George Washington University, Washington, DC, ¹⁵Division of Rheumatology, Department of Medicine, MedStar Georgetown University Hospital, Washington, DC, ¹⁶University of Michigan, Ann Arbor, MI
Background/Purpose: Interstitial lung disease (ILD) is the leading cause of death in patients with systemic sclerosis (SSc). Although pulmonary function tests (PFTs) are commonly used…
Abstract Number: 1170 • ACR Convergence 2020
Exploring the Use of Von Willebrand Factor as a Disease Biomarker in a Cohort of Patients with Juvenile Scleroderma: A Pilot Study
Natalia Vasquez-Canizares¹, Beamon Agarwal², Tamar Rubinstein³, Dawn Wahezi¹ and Morayma Reyes-Gil¹, ¹Albert Einstein College of Medicine, Bronx, NY, ²GenomeRxUS LLC, Clifton Heights, PA, ³Albert Einstein College of Medicine / Montefiore Medical Center, White Plains, NY
Background/Purpose: Juvenile Scleroderma (JScl) is a heterogenous disease characterized by autoimmunity, vasculopathy, and fibrosis. Morbidity and mortality remain high in part due to the continuing…
Abstract Number: 1907 • ACR Convergence 2020
DNASE1L3 R206C Polymorphism, a Systemic Sclerosis Risk Factor, Causes Impaired Digestion of Genomic DNA in Apoptosis-derived Extracellular Vesicles
Brian Skaug¹, Julio Charles¹, Jacob Couturier², Dorothy Lewis², Maureen Mayes³ and Shervin Assassi³, ¹University of Texas Houston, McGovern Medical School, Division of Rheumatology and Clinical Immunogenetics, Houston, TX, ²University of Texas Houston McGovern Medical School, Division of Infectious Diseases, Houston, TX, ³University of Texas Houston McGovern Medical School, Division of Rheumatology and Clinical Immunogenetics, Houston, TX
Background/Purpose: Two independent studies on genetic risk factors for systemic sclerosis (SSc) identified a polymorphism of Deoxyribonuclease 1-like 3 (DNASE1L3) associated with increased SSc risk. …
Abstract Number: 0401 • ACR Convergence 2020
Prevalence and Characteristics of Systemic Sclerosis Patients Fulfilling the 2019 EULAR/ACR Classification Criteria for Systemic Lupus Erythematosus
Ronald Bass¹, Duncan Moore² and Virginia Steen², ¹Georgetown University School of Medicine, Washington, DC, ²Division of Rheumatology, Department of Medicine, MedStar Georgetown University Hospital, Washington, DC
Background/Purpose: Literature describing the overlap syndrome of SSc and SLE is limited and has employed a range of case definitions. Our study sought to use…
Abstract Number: 1377 • ACR Convergence 2020
Raynaud’s Phenomenon and Systemic Sclerosis in Post-9/11 Deployed Veterans Receiving Care Veterans Health Administration Care
Tracy Frech¹, Maureen Murtaugh¹, Megan Amuan² and Mary Jo Pugh¹, ¹University of Utah and Salt Lake Veterans Affair Medical Center, Salt Lake City, UT, ²Veterans Affair Medical Center, Salt Lake City, UT
Background/Purpose: The purpose of this project was to describe Raynaud's phenomenon (RP), very early diagnosis of systemic sclerosis (VEDOSS), and systemic sclerosis (SSc) in Veterans…
Abstract Number: 1908 • ACR Convergence 2020
Establishment of iPSc and Differentiated Endothelial Cells of Systemic Sclerosis Associated Pulmonary Arterial Hypertension ; Functional and Molecular Analysis
Yuki Kudo¹, Masaru Kato², Yuhei Shibata¹, Michihito Kono², Yuichiro Fujieda², Olga Amengual², Kenji Oku² and Tatsuya Atsumi³, ¹Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan, ²Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Hokkaido, Japan, ³Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine, Hokkaido University, Sapparo, Hokkaido, Japan
Background/Purpose: Pulmonary arterial hypertension (PAH) occurs either primarily or in association with other diseases such as connective tissue diseases. PAH associated with systemic sclerosis (SSc-PAH)…
Abstract Number: 0913 • ACR Convergence 2020
Systemic Sclerosis Portends a Higher Risk of Conduction and Rhythm Disorders at Diagnosis and During Disease Course: Results from a US Population Based Study
Yasser Radwan¹, Reto Kurmann², Avneek Singh Sandhu³, Edward El-Am⁴, Cynthia Crowson², Eric Matteson⁵, Thomas Osborn², Kenneth Warrington⁶, Rekha Mankad² and Ashima Makol², ¹Mayo Clinic, Rochester, Minnesota, USA, Lansing, MI, ²Mayo Clinic, Rochester, Minnesota, USA, Rochester, MN, ³Mayo Clinic, Rochester, Minnesota, USA, Dayton, OH, ⁴Indiana University School of Medicine, Indianapolis, IN, ⁵Mayo Clinic College of Medicine and Science, Rochester, Minnesota, USA, Rochester, MN, ⁶Mayo Clinic, Rochester, MN
Background/Purpose: Cardiac involvement, including electrocardiogram (ECG) abnormalities, is associated with worse prognosis in systemic sclerosis (SSc). We studied the incidence, risk factors and outcomes of…
Abstract Number: 1379 • ACR Convergence 2020
Clinical Outcomes Among Participants with Diffuse Systemic Sclerosis Contracting COVID-19 During Clinical Studies of Lenabasum: A Case Series
Robyn Domsic¹, Lorinda Chung², Jerry Molitor³, Robert Spiera⁴, Bradley Bloom⁵, Barbara White⁶ and Quinn Dinh⁶, ¹University of Pittsburgh School of Medicine, Pittsburgh, PA, ²Stanford University School of Medicine and Palo Alto VA Health Care System, Palo Alto, CA, ³University of Minnesota, Minneapolis, MN, ⁴Division of Rheumatology, Hospital for Special Surgery, New York, New York, USA, New York, NY, ⁵Corbus Pharmaceuticals Inc, Norwood, MA, ⁶Corbus Pharmaceuticals, Norwood, MA
Background/Purpose: Patients with systemic sclerosis (SSc) may be at increased risk for severe outcomes with COVID-19, given the high rate of immunosuppressive medication use, underlying…

1
2
3
…
17
Next Page »